Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug
Executive Summary
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.
You may also be interested in...
Cipla Chief Calls For Invigorating Focus On Repurposed Drugs
Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
Home Gains Buoy Cipla In Q1 But US Momentum Pivotal
A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.
Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy
Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.